# Prenetics Global Limited (PRE) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.19, market value $316 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Prenetics Global Limited reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.2×**. Each dollar of revenue is priced at 2.2×.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -24.2%** (5-yr avg -17.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 62.5%**. Prenetics Global Limited keeps 62.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -36.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -40.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -24.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -54.1%**. Return on all capital, debt included, is -54.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -22.8%**. Each dollar of assets produces -22.8% of profit.

## Growth
- **Revenue growth (1 yr): 201.7%** (3-yr 91.5%/yr, 5-yr 7.2%/yr). Revenue grew 201.7% over the last year, against 7.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 27.8%**. Earnings per share rose 27.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.3×**. It would take 1.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.97** (quick 2.72). Current assets cover the next year's liabilities 2.97 times.
- **Altman Z-score: 5.04**. A Z-score of 5.04 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Prenetics Global Limited does not currently pay a dividend, but it returned -12.7% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Prenetics Global Limited; the consensus is strong_buy, with an average price target of $38.44 (+137% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 11.1%** (YTD 4.6%, 3-mo -11.1%). The shares are up 11.1% over twelve months including dividends.
- **From 52-week high: -40.6%** (42.5% above the low). Trading 41% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 34**. An RSI of 34 is neutral.
- **Beta (1 yr): 1.46** (volatility 82%). Beta of 1.46 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PRE · Page: https://foliofundamentals.com/stocks/pre

Not investment advice.